PURPOSE: A field study of postchemotherapy immune functioning relative to the use of taxanes is reported. Immune responses in breast cancer patients were analyzed as a function of whether patients received taxane as part of their adjuvant chemotherapy. EXPERIMENTAL DESIGN: Immune levels of 227 stage II/III breast cancer patients were measured immediately after surgery prior to chemotherapy and again 12 months later when all chemotherapies had been completed. T-cell blastogenesis and natural killer (NK) cell lysis levels of patients receiving taxanes (n = 55) were compared with levels of patients not receiving taxanes (n = 172). RESULTS: Regression analyses were conducted. The administration of taxane as part of combination chemotherapy predicted increased T-cell blastogenesis and NK cell cytotoxicity after the conclusion of all chemotherapies. For the Taxane group, average phytohemagglutinin-induced blastogenesis was 37% higher and NK cell cytotoxicity was 39% higher than the values for the No-Taxane group. CONCLUSIONS: Data from group comparisons with appropriate controls in a sizable clinical sample contravene traditional wisdom that taxanes suppress patients' immune cell functions. Problems in generalizing direct-contact laboratory models to the field of cancer treatment are highlighted.
PURPOSE: A field study of postchemotherapy immune functioning relative to the use of taxanes is reported. Immune responses in breast cancerpatients were analyzed as a function of whether patients received taxane as part of their adjuvant chemotherapy. EXPERIMENTAL DESIGN: Immune levels of 227 stage II/III breast cancerpatients were measured immediately after surgery prior to chemotherapy and again 12 months later when all chemotherapies had been completed. T-cell blastogenesis and natural killer (NK) cell lysis levels of patients receiving taxanes (n = 55) were compared with levels of patients not receiving taxanes (n = 172). RESULTS: Regression analyses were conducted. The administration of taxane as part of combination chemotherapy predicted increased T-cell blastogenesis and NK cell cytotoxicity after the conclusion of all chemotherapies. For the Taxane group, average phytohemagglutinin-induced blastogenesis was 37% higher and NK cell cytotoxicity was 39% higher than the values for the No-Taxane group. CONCLUSIONS: Data from group comparisons with appropriate controls in a sizable clinical sample contravene traditional wisdom that taxanes suppress patients' immune cell functions. Problems in generalizing direct-contact laboratory models to the field of cancer treatment are highlighted.
Authors: Barbara L Andersen; Lisa M Thornton; Charles L Shapiro; William B Farrar; Bethany L Mundy; Hae-Chung Yang; William E Carson Journal: Clin Cancer Res Date: 2010-06-08 Impact factor: 12.531
Authors: Albert A De Vera; Pranav Gupta; Zining Lei; Dan Liao; Silpa Narayanan; Qiuxu Teng; Sandra E Reznik; Zhe-Sheng Chen Journal: Cancer Lett Date: 2018-11-01 Impact factor: 8.679
Authors: Barbara L Andersen; Neha Godiwala Goyal; Travis D Westbrook; Brenden Bishop; William E Carson Journal: Clin Cancer Res Date: 2016-07-12 Impact factor: 12.531
Authors: Sharla Wells-Di Gregorio; Kristen M Carpenter; Caroline S Dorfman; Hae-Chung Yang; Laura E Simonelli; William E Carson Journal: Brain Behav Immun Date: 2011-07-23 Impact factor: 7.217
Authors: Ekaterina A Alyamkina; Evgenia V Dolgova; Anastasia S Likhacheva; Vladimir A Rogachev; Tamara E Sebeleva; Valeriy P Nikolin; Nelly A Popova; Konstantin E Orishchenko; Dmitriy N Strunkin; Elena R Chernykh; Stanislav N Zagrebelniy; Sergei S Bogachev; Mikhail A Shurdov Journal: Genet Vaccines Ther Date: 2009-08-14